This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Logo

Trial of a Virtual Exercise-based Rehabilitation Program to Treat Persistent Chemotherapy-Induced Peripheral Neuropathy (CIPN)

Sponsored by University Health Network, Toronto

About this trial

Last updated 2 months ago

Study ID

25-5957

Status

Not yet recruiting

Type

Interventional

Phase

Phase 3

Placebo

No

Accepting

18+ Years
All Sexes

Trial Timing

Started 2 months ago

What is this trial about?

The purpose of this study is to determine the effectiveness of the EX-CIPN program in reducing the strength of CIPN symptoms and CIPN-related disability and improving the ability to complete everyday activities. This will be done by determining whether it is better to receive the EX-CIPN program or better to receive no additional intervention. To do this, some of the participants in this study will get EX-CIPN and others will receive usual care. Those who receive usual care will be offered EX-CIPN upon study completion. The main question it aims to answer is: • Is EX-CIPN effective in improving CIPN symptoms for cancer survivors experiencing persistent CIPN? Participants in both study groups will be asked to: • Complete assessments at baseline, immediately post-intervention, and 3-months post-intervention Participants in the EX-CIPN group will be asked to: * Complete an additional aassessment at 6-months post-intervention * Complete a 10-week remote, individualized exercise program * Receive health coaching calls on weeks 2, 3, 4, 6, and 8 of the intervention * Wear a FitBit throughout the study to track physical activity and promote behaviour change

What are the participation requirements?

Inclusion Criteria

* diagnosed with any type of cancer

* received chemotherapy treatment as part of curative-intent therapy (no minimum dose)

* >6 months following chemotherapy completion with no current plans for further chemotherapy

* report Grade 1 or higher on the numbness and tingling severity item of the Common Terminology Criteria for Adverse Events (CTCAE) v 5.0

* neuropathic pain 3 or higher on the Neuropathic Pain 4 (DN4) (interview)

* capable of ambulation and transfers (with or without gait/transfer aid) (ECOG score 0-2)

* are able to communicate sufficiently in English to complete intervention, questionnaires, and consent

* have access to and able to operate videoconferencing

Exclusion Criteria

* currently meeting all recommendations from the physical activity guidelines for cancer survivors

* have any neurological conditions influencing cognition (i.e. dementia, Alzheimer's) and preventing safe or appropriate engagement with exercise recommendation

* have neuropathy that pre-existed chemotherapy receipt (i.e. diabetic neuropathy)

* currently enrolled in other rehabilitation or exercise-based interventions